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elderly (225±41 ms) than in younger patients (208±31 msec) (p<0.001). Increased atrial
refractory period and age > 70 years were independent factors of decreased AF inducibil-
ity. Conclusion : AF inducibility is paradoxically decreased in elderly patients. The AF
induction is facilitated by the presence of a short atrial refractory period in patients
younger than 70 years and programmed atrial stimulation should be interpreted cau-
tiously in these patients. In the opposite, the increase of atrial refractory period could pro-
tect the patients older than 70 years against AF induction.
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839-1 The Long-Term Effect of Surgical Myectomy on Survival 
in Patients With Obstructive Hypertrophic 
Cardiomyopathy
Steve R. Ommen, Iacopo Olivotto, Martin S. Maron, Sandro Betocchi, Franco Cecchi, 
Michael J. Ackerman, Bernard J. Gersh, Joseph A. Dearani, Hartzell V. Schaff, Rick A. 
Nishimura, Barry J. Maron, Mayo Clinic, Rochester, MN
Background: Surgical septal myectomy is the definitive treatment for relief of drug-refrac-
tory symptoms in hypertrophic cardiomyopathy (HCM). Recent data document reduced
survival when left ventricular outflow (LVOT) obstruction is present. However, the poten-
tial effects of myectomy on long-term survival are unresolved.
Methods: Overall mortality was assessed in 1337 HCM pts evaluated between 1983-
2001: (1) 289 consecutive pts underwent isolated surgical myectomy at Mayo Clinic for
advanced symptoms attributable to LVOT obstruction; (2) 228 other pts with LVOT
obstruction were managed without surgery; (3) 820 pts had nonobstructive HCM. Sur-
vival after myectomy was compared to age and sex matched general population, nonop-
erated obstructive pts, and nonobstructive pts.
Results: Patients were 45 ± 20 years old, 58% were males, LV wall thickness was 22 ± 6
mm, the average resting gradient was 68 ± 37mmHg among the pts with LVOT obstruc-
tion. Including 4 operative deaths (procedural mortality, 1.4%), survival after myectomy at
1, 5, and 10 years was 98%, 96%, and 83%, respectively. This survival did not differ sta-
tistically from the age and sex matched general population, nor the pts with nonobstruc-
tive HCM (98%, 95%, 88%). Myectomy pts had more favorable survival than nonoperated
obstructive pts (90%, 80%, and 67%, log-rank p <0.0001). Multivariate Cox modelling
with all relevant co-variates showed that myectomy (hazard ratio 0.20, p<0.0001) was
independently associated with more favorable long-term survival.
Conclusion: Surgical septal myectomy performed for the relief of LVOT obstruction and
severe drug-refractory symptoms is associated with long-term survival equivalent to that
of an age and sex matched general population. Although these data are retrospective
and nonrandomized, they strongly suggest that myectomy reduces the excess mortality
risk associated with the presence of LVOT obstruction.
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839-2 Mechanism of Systolic Anterior Motion and 
Regurgitation Post Septal Ablation in Hypertrophic 
Cardiomyopathy
Francesca Nesta, Danita M. Yoerger, Michael H. Picard, Michael A. Fifer, Igor F. Palacios, 
Gus J. Vlahakes, Robert A. Levine, Judy Hung, Massachusetts General Hospital, 
Boston, MA
Background: Systolic anterior motion of the mitral valve (SAM) in hypertrophic cardi-
omyopathy (HCM) is secondary to both outflow tract narrowing and primary structural
abnormalities of the mitral apparatus: the papillary muscles (PM) and leaflets are shifted
anteriorly into the LV outflow path, causing SAM with regurgitation (MR). Clinical obser-
vations suggest that relief of obstruction by septal ablation (SAb) does not always cause
resolution of SAM and MR. We tested the hypothesis that persistent SAM relates to mal-
position of the mitral apparatus, and that this finding can predict persistence of SAM.
Methods: We reviewed echoes of 30 patients with HCM before and 3 months post SAb.
We assessed anterior leaflet malposition by the antero-posterior projection of the coapta-
tion point onto the mitral annular diameter (A/D ratio) in early systole. MR was assessed
by proximal jet in the LAX view. Results: Most patients (22/30=73%) had SAM at 3
months despite successful SAb (gradient reduction > 50%), and had more anterior mal-
position and less MR reduction than those without SAM: A/D 0.44 vs 0.57, MR proximal
jet reduction by 7% vs 51%, p < 0.0001. Anterior malposition was also present prior to
SAb, with A/D < 0.4 being predictive of SAM post SAb (p<0.007). Conclusions: SAM
and its related MR are not always eliminated by SAb. MV malposition is a strong determi-
nant and predictor of SAM and MR reduction post SAb and may represent a new thera-
peutic target during ablation procedures. 
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839-3 Frequency, Spectrum, and Phenotype of Hypertrophic 
Cardiomyopathy Patients With Multiple Sarcomeric 
Mutations
Sara L. Van Driest, Steve R. Ommen, Melissa L. Will, Vlad C. Vasile, Susan Chung, A. 
Jamil Tajik, Bernard J. Gersh, Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background: Hypertrophic cardiomyopathy (HCM) is caused by pathogenic mutations
involving 8 genes that encode critical proteins comprising the sarcomere. Here, we deter-
mine the frequency, spectrum, and phenotype associated with complex genetic status
(i.e. > 1 sarcomeric mutation) in a cohort of unrelated patients (pts) evaluated at a tertiary
outpatient HCM clinic.
Methods: DNA was obtained from 389 unrelated HCM pts and analyzed for mutations in
myosin binding protein C encoded by MYBPC3, β -myosin heavy chain (MYH7), regula-
tory and essential light chains (MYL2 and MYL3), troponin T (TNNT2), troponin I
(TNNI3), α -tropomyosin (TPM1), and actin (ACTC) using polymerase chain reaction,
denaturing high performance liquid chromatography, and DNA sequencing. Clinical data
were extracted from pt records blinded to pt genotype.
Results: Of the 389 HCM pts, 151 (38.8%) harbored at least one putative pathogenic
mutation. Eleven pts (2.8% of total and 7.2% of genotyped subset) had 2 putative sarco-
meric mutations: compound MYBPC3 in 2 pts, MYBPC3 and MYH7 (3), MYBPC3 and
TNNT2 (2), MYBPC3 and TNNI3 (1), MYBPC3 and TPM1 (1), compound MYH7 (1), and
MYH7 and TNNT2 (1). When compared to pts with single sarcomeric mutations, or no
sarcomeric mutations, pts with multiple mutations were younger at diagnosis (21.7 ± 11
years vs 36.4 ± 17 vs 45.1 ± 19, p <0.005, had greater hypertrophy (maximum left ven-
tricular wall thickness = 24.6 ± 12 mm vs 22.8 ± 6 vs 20.7 ± 6, p <0.05), and more fre-
quently received an ICD (36% vs 24% vs 10%, p = 0.0002). However, those with multiple
mutations were not more likely to have had a surgical myectomy than those with a single
mutation or no identifiable sarcomeric mutation.
Conclusion: This study represents a comprehensive mutational analysis searching for
multiple genetic defects in a large HCM cohort from a single tertiary referral center. Com-
plex genetic status was found in nearly 3% of HCM pts. On average, pts with multiple sar-
comeric mutations were diagnosed 20 years earlier and displayed the greatest degree of
hypertrophy. The possibility of multiple mutations involving the sarcomere adds further
complexity to the development and implementation of clinical molecular genetic testing
for HCM.
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839-4 Treatment With Antioxidant N-Acetylcysteine Reverses 
Interstitial Fibrosis in a Mouse Model of Human 
Hypertrophic Cardiomyopathy Mutation
Natalia Tsybouleva, Tripti Halder, Rajnikant Patel, Silvia Lutucuta, Gilberto De Freitas, 
Masakuni Ishiyama, Blase Carabello, Ali J. Marian, Baylor College of Medicine, Houston, 
TX
The genetic basis of human hypertrophic cardiomyopathy (HCM) is known but the patho-
genesis of its phenotypes is unknown. We have generated transgenic mice by cardiac-
restricted expressing mutant cardiac troponin T (cTnT)-Q92 protein, known to cause
HCM in humans; which exhibits enhanced systolic function, interstitial fibrosis (IF) and
myocyte disarray. Since oxidative stress is implicated in the pathogenesis of fibrosis, we
tested whether treatment with anti-oxidant N-acetyl cysteine (NAC) could reverse or
attenuate IF in the cTnT-Q92 mice. We performed a placebo-controlled study and ran-
domized 24 mice to placebo or NAC (1g/Kg/d) and include 12 non-transgenic (NTG) mice
as controls. We performed echocardiography prior to and after 16 weeks of therapy fol-
lowed by histological and molecular characterization. Transgenic mice had higher left
ventricular (LV) ejection fraction and smaller LV end systolic diameter and smaller heart
weight/body weight (HW/BW) as compared to NTG mice at the baseline. No significant
differences in the body weight, male/female ratio, mean age, and heart rates were
present among the three groups. Treatment with NAC reduced concentrations of alondi-
aldehyde and 4-hydroxy-2(E)-nonenal, indices of oxidative stress, in the left ventricular
tissue (NTG: 3.0 ± 0.6; Placebo: 3.5 ± 0.4; NAC: 2.3 ± 0.3, p=0.01). Similarly, collagen
volume fraction (CVF) was normalized (NTG: 3.4% ± 0.9; Placebo: 7.8 ± 1.7; NAC: 3.8 ±
